the first instillation, the patient felt feverish and developed a temperature of 39°C and chills. The treatment was stopped.
Two months later, the patient was admitted to the hospital because of fever, chills, weight loss (7 kg in 4 weeks), and fatigue. At admission, he had pancytopenia (absolute neutrophil count, 0.6 ϫ 10 9 /L; hemoglobin level, 10 g/dL; and absolute platelet count, 80 ϫ 10 9 /L). Blood cultures were sterile, and acid-fast staining of blood and sputum smears was negative. Acid-fast bacilli were identified in urine, and culture of urine yielded M. bovis-BCG. A chest roentgenogram was clear. Epithelioid cell granulomas with polynucleated giant cells, without caseous necrosis, were seen in a bone marrow biopsy specimen, and culture of the bone marrow aspirate yielded M. bovis-BCG.
Isoniazid, rifampin, and ethambutol treatment was prescribed, and there was a good clinical response. Hematologic abnormalities returned to normal over the 3 weeks following the beginning of treatment. Two months later, his clinical status worsened, and a CT scan of the abdomen detected the presence of a large solid-appearing mass in the left kidney and a thrombus of the left renal vein that extended into the inferior vena cava. A diagnosis of renal cell carcinoma was suspected. The patient's subsequent course was characterized by progressive anasarca, and he died 7 weeks later.
BCG is a live strain of M. bovis that, although attenuated, may exhibit some invasive properties. The developmental course of the systemic reaction and the correlation of its intensity with the BCG dose suggest that the reaction is, at least partly, hypersensitive. However, systemic invasion of BCG after intravesical administration is known to occur at a higher frequency when there is a breach in the integrity of the urogenital mucosa [1, 2] . Pneumonitis or hepatitis, which has been reported to occur in 0.7% of BCG-treated patients, has been attributed to systemic infection [1, 3] . Cytopenia, described in 0.1% of patients [2] , is also considered to be a symptom of systemic infection. However, when granulomas are typically seen in liver or bone marrow biopsy specimens, organisms often are not found by acid-fast staining, culture, or even DNA hybridization studies. Therefore, it has been proposed that many of these reactions are hypersensitive rather than infectious in nature [4] because of the inability to detect BCG in blood cultures even when systemic complications exist [5] .
For our two patients, identification of M. bovis in the bone marrow aspirates by culture showed that the medullary granulomas were caused by BCG infection of the bone marrow via hematogenous dissemination after bladder instillation and were not hypersensitive reactions. Chronic fatigue syndrome (CFS), an elusive and controversial illness, has been a difficult management problem for clinicians. A number of infectious agents have been implicated as the cause of CFS, although consistent and compelling evidence is still lacking [1] . Few well-documented infections could cause persistent inflammatory reaction leading to the symptomatology of CFS [2, 3] . Chlamydia pneumoniae is a common cause of respiratory infection and has been demonstrated within plaques of the coronary arteries years after initial infection [4] . Recently demonstrated replication of C. pneumoniae within human macrophages and endothelial cells [5] and a potent inducer of proinflammatory cytokines, such as TNF-␣ and IL-1 [6], raised the possibility of chronic infection that leads to persistent inflammatory response. A previous study failed to demonstrate elevated titers of antibody to C. pneumoniae in 50 patients with CFS [7] , although fatigue is a common symptom reported by patients for whom sputum cultures are persistently positive for C. pneumoniae [8] .
Over the past 3 years, we encountered 10 of 171 patients with symptoms of chronic fatigue who had elevated titers of antibody to C. pneumoniae long after initial respiratory infection. Most patients had favorable clinical and serological responses to a 1-to 2-months course of azithromycin therapy, although relapse was common. The clinical symptoms of and titers of antibody to C. pneumoniae for our 10 patients over the course of treatment are summarized in table 1.
A 32-year-old female developed pharyngitis, cough, cervical lymphadenopathy, low-grade fevers, severe fatigue, and myalgia in January 1993 (patient 1). A medical evaluation showed a normal complete blood cell count and normal results of thyroid function test and serum chemistry analysis. IgG antibody to Epstein-Barr virus was positive. During the following 3 years, the patient had frequent relapses of severe fatigue, diffuse myalgia, night sweats, pharyngitis, headaches, insomnia, and painful, swollen cervical lymph nodes (especially following exertion) that resulted in total disability.
Repeated evaluation in August 1996 revealed small nontender anterior cervical lymph nodes. Results of routine laboratory studies and serologies for several viruses were unremarkable. The titer of IgG antibody to C. pneumoniae was 1:256. Magnesium sulfate injections and salt loading failed to alleviate symptoms. One month later, when the patient was having increasing fatigue, the titer of antibody to C. pneumoniae rose to 1:1,024. Azithromycin (500 mg) was administered by mouth the first day, followed by NOTE. Titers are expressed as the reciprocal of the end point dilution of total antibody to C. pneumoniae (determined at Specialty Laboratory, Santa Monica, CA). All patients had negative titers of IgM antibody. All assays were performed with calibration standards of known antibody titers. CFS ϭ chronic fatigue syndrome (patients fulfilled the required criteria for the diagnosis of CFS as defined in [1] ); LN ϭ lymphadenopathy; . . . ϭ titer not determined.
* Relapse of symptoms. † Repeated titer after 1 month without treatment. All relapsed patients were subsequently treated with one or more courses of azithromycin.
